Daniel Weissberger
Overview
Explore the profile of Daniel Weissberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weissberger D, Stenzel M, Hunter L
Molecules
. 2024 Oct;
29(20).
PMID: 39459317
Covalent drugs can offer significant advantages over non-covalent drugs in terms of pharmacodynamics (i.e., target-binding properties). However, the development of covalent drugs is sometimes hampered by pharmacokinetic limitations (e.g., low...
2.
Richardson N, OMalley L, Weissberger D, Tumber A, Schofield C, Griffith R, et al.
Bioorg Med Chem
. 2021 Apr;
38:116115.
PMID: 33862469
Prolyl hydroxylase (PHD) enzymes play a critical role in the cellular responses to hypoxia through their regulation of the hypoxia inducible factor α (HIF-α) transcription factors. PHD inhibitors show promise...
3.
Pang C, Ballouz S, Weissberger D, Thibaut L, Hamey J, Gillis J, et al.
Mol Cell Proteomics
. 2020 Aug;
19(11):1876-1895.
PMID: 32817346
Co-fractionation MS (CF-MS) is a technique with potential to characterize endogenous and unmanipulated protein complexes on an unprecedented scale. However this potential has been offset by a lack of guidelines...
4.
Jwad R, Weissberger D, Hunter L
Chem Rev
. 2020 Aug;
120(17):9743-9789.
PMID: 32786420
Cyclic peptides are promising scaffolds for drug development, attributable in part to their increased conformational order compared to linear peptides. However, when optimizing the target-binding or pharmacokinetic properties of cyclic...